Glucagon-Like Peptide-1 (GLP-1) receptor agonists are medicines indicated for the treatment of diabetes and for weight management in patients living with obesity or overweight with weight-related health conditions.

Public interest around these medicines, mostly around their use for weight-loss, has grown considerably in the last years. From academic and medical discussions to social media, from gossip to celebrity endorsements, GLP-1s are everywhere.

Join our Instagram LIVE with Dr. Bart Van der Schueren, EMA expert and President of the Belgian Association for the Study of Obesity.

We’ll explore GLP-1s — from what they are and how they work to how they are used in clinical practice.

Tune in on Monday, 22 July at 18:00 on the joint Health and Environment agencies’ Instagram account @one_healthenv_eu managed with our sister agencies European Food Safety Authority (EFSA), European Environment Agency (EEA), European Centre for Disease Prevention and Control (ECDC) and European Chemicals Agency (ECHA). 

This is an opportunity to get your questions answered!